School of Medicine
Showing 261-280 of 423 Results
-
Mindie H. Nguyen, MD, MAS, AGAF, FAASLD
Professor of Medicine (Gastroenterology and Hepatology) and, by courtesy, of Epidemiology and Population Health
Current Research and Scholarly InterestsWe conduct clinical trials and epidemiological, translational, and real-world studies of liver cancer, fatty liver (NASH, NAFLD), viral hepatitis B and C, liver cirrhosis, and liver transplant. We focus on risk identification for disease prevention and treatment for improvement of survival. We focus on sex, racial/ethnic, and socioeconomic disparities. We specialize in clinical trials, large international real-world consortium registry data, and large public/semi-public databases.
-
Minh Nguyen
Contingent Employee, Medicine - Med/Cardiovascular Medicine
BioPrevious bio as a PhD student:
@DARE fellow (Diversifying Academia, Recruiting Excellence) https://vpge.stanford.edu/people/minh-nguyen
@Data Science Scholar https://datascience.stanford.edu/people/minh-nguyen -
Quan Dong Nguyen, MD, MSc
Professor of Ophthalmology and, by courtesy, of Pediatrics and of Medicine (Immunology & Rheumatology)
Current Research and Scholarly InterestsWe have focused our research on the development of novel therapies and innovative assessment and diagnostic imaging technologies for retinal vascular and ocular inflammatory disorders, specifically diabetic retinopathy (DR), age-related macular degeneration (AMD) and uveitis. Building on our initial work describing the role of hypoxia and vascular endothelial growth factor (VEGF) in diabetic retinopathy (DR) and diabetic macular edema (DME), We have become interested in the biochemical mechanisms that would presumably lead to DME. During the past decade, our research has contributed to the body of evidences that defines the important role of anti-VEGF therapies in DME and AMD, as well as the role of the mTOR pathway and various interleukins in the pathogenesis of uveitis.
We have launched a productive and well-funded clinical research program while at the same time providing clinical care to patients with uveitis and retinal vascular diseases and fulfilling significant teaching and administrative assignments. We have established a number of key collaborators both within and outside the institutions. In addition, we have also established Center in Baltimore and now in Silicon Valley, which has excelled in conducting proof-of concept, early-phase multi-center clinical trials and studies, exploring the clinical disease manifestations and the efficacy of various pharmacologic agents in retinal, uveitic, and ocular inflammatory disorders.
